StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note published on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Price Performance
NASDAQ:GLMD opened at $7.33 on Monday. The company has a market cap of $36.98 million, a P/E ratio of -3.05 and a beta of 0.67. Galmed Pharmaceuticals has a 1 year low of $2.73 and a 1 year high of $23.80. The stock’s fifty day moving average price is $4.37 and its two-hundred day moving average price is $4.27.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last issued its earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 EPS for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Stories
- Five stocks we like better than Galmed Pharmaceuticals
- What is the FTSE 100 index?
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- Using the MarketBeat Dividend Yield Calculator
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
